Group One Trading’s Y-mAbs Therapeutics YMAB Stock Holding History

Group One Trading’s Portfolio YMAB Stock Details YMAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-100	Closed	-$1.17K	–	8639
2022 Q1	$1K	Buy	+100	New	+$1.03K	﹤0.01%	7891

Other funds holding YMAB

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Group One Trading's YMAB Position: Q2 2022 in Review

Group One Trading sold out of Y-mAbs Therapeutics (YMAB) in Q2 2022, closing a stake of 100 shares — an estimated $1.17K sold.

Group One Trading first reported a position in YMAB in Q1 2022 and held it in 1 quarter. The position peaked at $1K in Q1 2022. 91 funds tracked by Wall St. Rank hold YMAB as of Q2 2022.

Group One Trading reported no remaining Y-mAbs Therapeutics position as of Q2 2022 after selling out during the quarter.
Group One Trading sold 100 Y-mAbs Therapeutics shares in Q2 2022, an estimated $1.17K.
Group One Trading first reported a position in Y-mAbs Therapeutics in Q1 2022 and held it in 1 quarter.
Group One Trading's Y-mAbs Therapeutics position peaked at $1K in Q1 2022.
91 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q2 2022.

Based on Group One Trading's 13F filing for Q2 2022, filed 11 Aug 2022.